id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-343018-8ghon5nb	Rajabally, Yusuf A.	Management challenges for chronic dysimmune neuropathies during the COVID‐19 pandemic	2020-04-24		.txt	text/plain	1848	106	33	Suggested clinical management guidance for incident patients with CIDP, MMN, and anti-MAG neuropathy during the COVID-19 pandemic 11 and its derivative the Overall Neuropathy Limitation Scale (ONLS) 12 are easy and rapid to administer. 20 The need for treatment for a newly identified patient with chronic dysimmune neuropathy also concurrently infected by COVID-19 will likely be a rare occurrence, and treatment delay is probably appropriAlso of concern, the infection risk with immunosuppressants probably lasts for several months after interruption (although there are only few studies of single agents used for sufficiently long to confirm this). 42 In the case of patients at high risk of severe infection and death from COVID-19, but who will remain seronegative, the question of when the re-implementation of routine face-to-face consultations, usual hospital or infusion center treatment and use of immune suppressive therapies, particularly corticosteroids, will become safe again, is, disturbingly, unanswered.	./cache/cord-343018-8ghon5nb.txt	./txt/cord-343018-8ghon5nb.txt